The U.S. Food and Drug Administration has scheduled a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review modified risk tobacco product (MRTP) applications from Swedish Match USA for 20 ZYN nicotine pouch products. These ZYN pouches—already authorized for sale through the premarket tobacco product application (PMTA) pathway in January 2025—include flavors such as Cool Mint, Citrus, Coffee, Peppermint, and Wintergreen, each offered in 3 mg and 6 mg strengths. Swedish Match is asking permission to market the pouches with the claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

Under federal law, MRTP applications must show that a product, as actually used by consumers, reduces individual health risks and benefits population health overall. TPSAC’s review will concentrate on the scientific evidence about ZYN’s relative health risks, whether consumers understand the proposed claim, and the potential public health impact of granting a modified risk order. The meeting will be held virtually, will be open to the public, and will be captioned and recorded.

The public may submit comments to Docket No. FDA-2025-N-0835 through January 21, 2026; comments received by January 7 will be provided directly to TPSAC. The FDA is also inviting individuals to request time for oral presentations during the meeting’s public comment period. Redacted MRTP application materials are available on the FDA website. The agency will consider all public input and TPSAC’s recommendations before issuing a final decision.

This article was adapted from an original report published on tobaccoreporter.com. All rights belong to the original publisher.